Newsbenzinga
Penny Stock Neumora Therapeutics Cuts Workforce After Depression Trials Fail
· Published
Article summary
Neumora Therapeutics ends navacaprant development after Phase 3 depression trial setbacks, cuts workforce by 35%.
An excerpt from the original article.
Comments —
Loading comments…